Αρχική World News News digest – dinosaur bone cancer, YouTube junk food ad ban and...

News digest – dinosaur bone cancer, YouTube junk food ad ban and COVID-19 updates

Doctors diagnose cancer in a dinosaur

The horned dinosaur, originally excavated in 1989, was originally thought to have a leg fracture that hadn’t healed properly. But a team of scientists have since diagnosed the plant-eating Centrosaurus with osteosarcoma, a type of bone cancer. The dinosaur, which lived around 77 million years ago, is thought to be one of the oldest examples of cancer. Scientists say studying the fossilised remains could help to uncover more about the evolutionary origins of disease. Read the full story at Science Mag.

NHS to roll out “COVID-friendly” cancer treatments

The £160 million initiative will pay for drugs that require fewer hospital visits or have fewer side-effects affecting the immune system, both of which can leave patients more susceptible to infection. Since the pandemic began, almost 2,000 people have been given these therapies, which has allowed their treatment to continue rather than being delayed or halted.

Text reminders boost screening uptake

Campaigners are urging the NHS to send text reminders to everyone invited for screening, after the SMS iniative boosted cervical screening participation by around 5% in a recent study by Imperial.  Currently, only 34% of GP practices are able to send text reminders for screening invites. More on this at The Times (£).

Google to block junk food ads for under-18s

The Daily Mail reports on Google’s ‘junk food crackdown’, banning junk food adverts being shown to children in the UK on all its platforms, including YouTube. The announcement comes a week after the UK Government launched a new strategy to tackle obesity, including restrictions on junk food marketing on TV and online. While the move is a step in the right direction, age verification doesn’t always work as well as it should, which is why we’ve called for a 9pm watershed.

Not all cancer patients ‘vulnerable’ to COVID-19

A group of oncologists have argued that not all cancer patients should be considered vulnerable to COVID-19, reports the Pharmaceutical Journal. They’re calling for evidence-based treatment decisions, which will be helped by the data collected on people with cancer’s experience during the pandemic. In similar news, BBC covered new study findings that suggest continuing chemotherapy and immunotherapy may not pose a risk for some cancer patients with COVID-19.

“The NHS must never again be a COVID-only service.”

Experts are urging NHS bosses not to impose the same mass closure of services that were introduced in March if a second wave of COVID-19 hits, reports The Guardian. We’ve blogged before about what needs to happen to get cancer services back on track during the coronavirus pandemic.

And finally…

More than two million people in England, Scotland and Northern Ireland can now leave their home and return to work, as shielding ends. People shielding in Wales have been advised to continue until 16 August. Read more at BBC.

Scarlett Sangster is a writer for PA Media Group

More on this topic



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,434ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

The Combination of Nivolumab and Cabozantinib Provides a New First-Line Treatment Option in Advanced Clear Cell RCC

Efficacy data with nivolumab plus cabozantinib showing improved survival and response rates, together with an acceptable safety profile presented by Prof. Toni K. Choueiri...

News digest – calorie guidelines, reduced lung cancer referrals and COVID-19’s impact on cancer services

Image was taken before the coronavirus pandemic. Urgent lung cancer referrals down during lockdown Of all cancer types, those with suspected lung cancer were the...

“If there is an under-representation of ethnic minority communities, there will be a lack of understanding”

Nikki and her son Amarvir, who was diagnosed with acute lymphoblastic leukaemia in 2010. We spoke to Siobhan, Nikki and Jessica about their experiences...

How to Strengthen Your Immune System: Part 2

Yesterday, we learned how certain foods and changes to our diet can help boost our immune system, which is especially important during this pandemic....

ACS’s Updated Cervical Cancer Screening Guidelines Explained

September 18, 2020, by NCI Staff A cervical specimen with a pap stain that identifies cervical cancer. Credit: National Cancer Institute Routine cervical cancer screening is very...

Access to Cancer Medicines and Clinical Trials Show Stark Variations Across Europe [ESMO Press Release]

LBA66_PR - Disparities in access to oncology clinical trials in Europe in the period 2009-2019 A. Carneiro1, T.M.S. Amaral2, M. Brandao3, M. Scheffler4, K. Bol5,...